菜单

CRO Services

Drug Development Expertise Empowering Research Services for Biologics

 

Advance bispecifics from concept to preclinical candidates remains challenging, requiring comprehensive insights and technical expertise at every stage. WuXi Biologics’ end-to-end discovery approach, spanning molecular design, biology-driven platform selection, HTP screening/production, and tailored in vitro/in vivo studies, facilitate a seamless transition into CMC development.

 

Download the poster to discover:

 

  • How to choose bsAb formats and modalities (valency, geometry, synapse distance, PK, developability)
  • High-throughput production, binding, and cell assays (ELISA, BLI, SPR, flow cytometry) for rapid screening
  • In vitro cytotoxicity, cytokine profiling, and NHP PK/PD studies for lead characterization​

 

 

 

Enter your details to download the poster